您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Onartuzumab
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Onartuzumab
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:1133766-06-9
包装与价格:
包装价格(元)
1mg电议
5mg电议

产品名称
MetMAb
产品介绍
Onartuzumab (MetMAb) 是一种人源化亲和成熟的单价单克隆抗体,抑制受体酪氨酸激酶MET。Onartuzumab 可有效抑制 HGF 结合、受体磷酸化和信号转导。Onartuzumab 具有抗体样药代动力学和抗肿瘤活性。
生物活性

Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against theMETreceptor. Onartuzumab potently inhibitsHGFbinding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity[1].

体外研究
(In Vitro)

Onartuzumab acts specifically by blocking HGF α-chain (but not β-chain) binding to MET[1].
Onartuzumab blocks HGF binding to human c-Met with an inhibitory concentration (IC)50 of 1.8 nM and inhibits the subsequent induction of c-Met auto-phosphorylation and cell proliferation in many cancer cell lines[2].

体内研究
(In Vivo)

Onartuzumab (30 mg/kg, IP, twice a week for 2 mouth) suppresses tumor growth[3].

Animal Model:Human HGF-transgenic SCID mice implanted with BxPC3 tumor cells, nude (nu/nu) mice implanted with KP4 human pancreatic xenograft tumor cells[3]
Dosage:30 mg/kg
Administration:IP, twice a week for 2 mouth
Result:Suppressed tumor growth, but did not affect the mean in vivo human HGF levels.
Animal Model:U-87 MG tumor-bearing mice[3]
Dosage:30 mg/kg
Administration:IP, once
Result:Resulted in profound TGI (tumor growth inhibition) with 4/10 mice demonstrating a partial response (>50% reduction in tumor size) and 6/10 mice demonstrating a complete response (100% tumor regression).
Clinical Trial
CAS 号

1133766-06-9

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.